MedKoo Cat#: 126311 | Name: (S)-C12-200
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(S)-C12-200 is an ionizable cationic lipid (pKa = 7.12) and an isomer of C12-200.

Chemical Structure

(S)-C12-200
(S)-C12-200
CAS#1226552-44-8 (S)

Theoretical Analysis

MedKoo Cat#: 126311

Name: (S)-C12-200

CAS#: 1226552-44-8 (S)

Chemical Formula: C70H145N5O5

Exact Mass: 1136.1246

Molecular Weight: 1136.96

Elemental Analysis: C, 73.95; H, 12.86; N, 6.16; O, 7.04

Price and Availability

Size Price Availability Quantity
10mg USD 450.00 2 Weeks
25mg USD 850.00 2 Weeks
50mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
(S)-C12-200; C12-200-S
IUPAC/Chemical Name
1,1′-[[2-[4-[2-[[2-[bis[(2S)-2-hydroxydodecyl]amino]ethyl][(2S)-2-hydroxydodecyl]amino]ethyl]-1-piperazinyl]ethyl]imino]bis-2-dodecanol
InChi Key
RVHYPUORVDKRTM-KZILWRTPSA-N
InChi Code
InChI=1S/C70H145N5O5/c1-6-11-16-21-26-31-36-41-46-66(76)61-73(58-60-75(64-69(79)49-44-39-34-29-24-19-14-9-4)65-70(80)50-45-40-35-30-25-20-15-10-5)57-55-71-51-53-72(54-52-71)56-59-74(62-67(77)47-42-37-32-27-22-17-12-7-2)63-68(78)48-43-38-33-28-23-18-13-8-3/h66-70,76-80H,6-65H2,1-5H3/t66-,67?,68?,69-,70-/m0/s1
SMILES Code
CCCCCCCCCC[C@H](O)CN(CCN1CCN(CCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)CC1)CCN(C[C@@H](O)CCCCCCCCCC)C[C@@H](O)CCCCCCCCCC
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,136.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Khare P, Dave KM, Kamte YS, Manoharan MA, O'Donnell LA, Manickam DS. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells. AAPS J. 2021 Dec 6;24(1):8. doi: 10.1208/s12248-021-00653-2. PMID: 34873640; PMCID: PMC8648339. 2: Barbieri BD, Peeler DJ, Samnuan K, Day S, Hu K, Sallah HJ, Tregoning JS, McKay PF, Shattock RJ. The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA. J Control Release. 2024 Oct;374:280-292. doi: 10.1016/j.jconrel.2024.08.016. Epub 2024 Aug 21. PMID: 39142355. 3: Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW, DeRosa F, Mir FF, Fenton OS, Anderson DG. Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett. 2015 Nov 11;15(11):7300-6. doi: 10.1021/acs.nanolett.5b02497. Epub 2015 Oct 20. PMID: 26469188. 4: Meulewaeter S, Aernout I, Deprez J, Engelen Y, De Velder M, Franceschini L, Breckpot K, Van Calenbergh S, Asselman C, Boucher K, Impens F, De Smedt SC, Verbeke R, Lentacker I. Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria. J Control Release. 2024 Jun;370:379-391. doi: 10.1016/j.jconrel.2024.04.052. Epub 2024 May 4. PMID: 38697317. 5: Borrajo ML, Quijano A, Lapuhs P, Rodriguez-Perez AI, Anthiya S, Labandeira- Garcia JL, Valenzuela R, Alonso MJ. Ionizable nanoemulsions for RNA delivery into the central nervous system - importance of diffusivity. J Control Release. 2024 Aug;372:295-303. doi: 10.1016/j.jconrel.2024.06.051. Epub 2024 Jun 24. PMID: 38909703. 6: Mrksich K, Padilla MS, Joseph RA, Han EL, Kim D, Palanki R, Xu J, Mitchell MJ. Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length. J Biomed Mater Res A. 2024 Sep;112(9):1494-1505. doi: 10.1002/jbm.a.37705. Epub 2024 Mar 15. PMID: 38487970; PMCID: PMC11239295. 7: Oza D, Ivich F, Pace J, Yu M, Niedre M, Amiji M. Lipid nanoparticle encapsulated large peritoneal macrophages migrate to the lungs via the systemic circulation in a model of clodronate-mediated lung-resident macrophage depletion. Theranostics. 2024 Apr 8;14(6):2526-2543. doi: 10.7150/thno.91062. PMID: 38646640; PMCID: PMC11024852. 8: Melamed JR, Hajj KA, Chaudhary N, Strelkova D, Arral ML, Pardi N, Alameh MG, Miller JB, Farbiak L, Siegwart DJ, Weissman D, Whitehead KA. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. J Control Release. 2022 Jan;341:206-214. doi: 10.1016/j.jconrel.2021.11.022. Epub 2021 Nov 18. PMID: 34801660; PMCID: PMC8905090. 9: Borrajo ML, Lou G, Anthiya S, Lapuhs P, Álvarez DM, Tobío A, Loza MI, Vidal A, Alonso MJ. Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines. Drug Deliv Transl Res. 2024 Aug;14(8):2046-2061. doi: 10.1007/s13346-024-01635-5. Epub 2024 May 29. PMID: 38811465; PMCID: PMC11208213. 10: Da Silva Sanchez AJ, Zhao K, Huayamares SG, Hatit MZC, Lokugamage MP, Loughrey D, Dobrowolski C, Wang S, Kim H, Paunovska K, Kuzminich Y, Dahlman JE. Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery. J Control Release. 2023 Jan;353:270-277. doi: 10.1016/j.jconrel.2022.11.037. Epub 2022 Nov 30. PMID: 36423872; PMCID: PMC9897220. 11: Hajj KA, Melamed JR, Chaudhary N, Lamson NG, Ball RL, Yerneni SS, Whitehead KA. A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo. Nano Lett. 2020 Jul 8;20(7):5167-5175. doi: 10.1021/acs.nanolett.0c00596. Epub 2020 Jun 9. PMID: 32496069; PMCID: PMC7781386.